scholarly journals Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry

2021 ◽  
Vol 32 (5) ◽  
pp. 678-679
Author(s):  
D.H. Kwon ◽  
R. Vashisht ◽  
H.T. Borno ◽  
R.R. Aggarwal ◽  
E.J. Small ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Health System ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
University Of California ◽  
The University

Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 37-37
Author(s):  
Daniel Kwon ◽  
Rohit Vashisht ◽  
Hala Borno ◽  
Rahul Raj Aggarwal ◽  
Eric Jay Small ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Health System ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Host Cells ◽  
University Of California ◽  
Registry Study ◽  
Medical Centers ◽  
Chi Squared ◽  
The University

37 Background: SARS-CoV-2 entry into host cells is facilitated by the transmembrane protease TMPRSS2. TMPRSS2 expression can be modulated by the androgen receptor. It is unclear whether androgen deprivation therapy (ADT) may partially protect from SARS-CoV-2 infection. Methods: A retrospective registry study of adult men with prostate cancer who underwent testing for SARS-CoV-2 in the UC Health System between February 1, 2020 and October 6, 2020 was performed. The University of California Health COVID Research Data Set (UC CORDS), which includes electronic health data of all patients who underwent testing for SARS-CoV-2 at 5 UC academic medical centers (UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco) and 12 affiliated hospitals across California, was used. Association of SARS-CoV-2 infection and receipt of ADT (GnRH agonist or antagonist) within 90 days of COVID testing was determined using the Chi-Squared test. Analyses (Chi-Squared or Fisher’s exact tests) were also performed in race/ethnicity subgroups. Results: Overall, 2,948 men with prostate cancer who underwent SARS-CoV-2 testing were identified, of whom 59 (2.0%) tested positive. Of the 2,948 men, 2,124 (72%) were White; 219 (7%) Black or African-American; 182 (6%) Asian or Native Hawaiian/Pacific-Islander; 176 (6%) Other race; and 247 (8%) Unknown race. There were 235 (8%) Hispanic or Latino men. Among the 444 men who received ADT in the entire cohort, 7 (1.6%) tested positive, and among the 2,504 men who did not receive ADT, 52 (2.1%) tested positive (OR 0.76, 95% CI 0.34-1.67, P = 0.49). No statistically significant association between ADT and SARS-CoV-2 positivity was found within race or ethnicity subgroups. Conclusions: No association between the use of ADT and the risk of testing positive for SARS-CoV-2 was identified in this study of a diverse patient population in the University of California Health System medical centers and hospitals. In this setting of an overall low prevalence of SARS-CoV-2 infection, thus far, there is no strong evidence of a protective benefit of ADT.

Proportion of biochemically-recurrent prostate cancer patients with durable undetectable PSA after short-course androgen deprivation therapy.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 207-207
Author(s):  
Daniel M. Lim ◽  
Roman Gulati ◽  
Serge Aleshin-Guendel ◽  
Heather H. Cheng ◽  
Agnes M. Gawne ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Specific Antigen ◽  
Initial Therapy ◽  
Androgen Deprivation ◽  
Clinical Value ◽  
Short Course ◽  
Increased Risk ◽  
The University ◽  
Trial Endpoint

207 Background: Optimal utilization of novel therapies for advanced prostate cancer is challenging without a validated surrogate efficacy endpoint. Ongoing trials are using durable undetectable prostate specific antigen (PSA) levels as a marker of efficacy. The proportion of patients and clinical relevance of those with a prolonged undetectable PSA after a short course of androgen deprivation therapy (ADT) is uncertain. Methods: The University of Washington Caisis database was queried for radical prostatectomy patients who received 6–12 months of ADT after biochemical recurrence (BCR), defined as PSA ≥ 0.2 ng/mL and no radiographically detectable metastasis. Proportions of patients with undetectable PSA 12 and 24 months after ending ADT were compared to a hypothesized 5% rate using exact binomial tests. Associations with patient and tumor characteristics were examined using logistic regression, and associations with risk of subsequent metastasis and death from any cause were evaluated by log-rank tests. Results: After ineligibility exclusions, data were abstracted from 93 patients. Proportions of patients with undetectable PSA 12 and 24 months after ending ADT were n=23/93 (24.7%; 95% CI 16.4–34.8%; P<0.001) and n=14/93 (15.1%; 95% CI 8.5–24.0%; P<0.001), respectively. Proportions of patients with undetectable PSA 12 and 24 months after testosterone recovery ≥ 50 ng/dL were n=16/65 (24.6%; 95% CI 14.8-36.9%) and n=10/65 (15.4%; 95% CI 7.6-26.5%), respectively. Being 1 year older at diagnosis was associated with an 11.5% (95% CI 3.1–21.9%; P=0.01) increase in the odds of having a detectable PSA after controlling for PSA at diagnosis, Gleason sum and time from initial therapy to BCR. Detectable PSA was associated with increased risk of metastasis (P=0.006) with marginal evidence of association with death from any cause (P=0.07). Conclusions: This single-institution retrospective analysis shows that it is not uncommon to have undetectable PSA 12 or 24 months after a short course of ADT. Additional analysis is needed to demonstrate the clinical value of this measure as a surrogate for prostate cancer outcomes and for consideration as a trial endpoint.

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

199: Health Care Cost Associated with Prostate Cancer, Androgen Deprivation Therapy, and Bone Complications

2006 ◽  
Vol 175 (4S) ◽  
pp. 65-65
Author(s):  
Tracey L. Krupski ◽  
Kathleen A. Foley ◽  
Onur Baser ◽  
Stacey R. Long ◽  
David Macarios ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Health Care ◽  
Androgen Deprivation Therapy ◽  
Health Care Cost ◽  
Androgen Deprivation ◽  
Bone Complications

128: Androgen Deprivation Therapy and Risk of Diabetes Mellitus in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer

2006 ◽  
Vol 175 (4S) ◽  
pp. 41-41
Author(s):  
Matt C. Kincade ◽  
Ithaar H. Derweesh ◽  
John Malcolm ◽  
Kimberly D. Lamar ◽  
Anthony L. Patterson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation

The relationship between PTEN mutations and resistance to androgen-deprivation therapy in prostate cancer

2018 ◽  
Author(s):  
Abdallah Alzoubi ◽  
Aya Alsmairat ◽  
Bashir Samir Al ◽  
Mahmoud Alfaqih ◽  
Khalid Kheirallah
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
The Relationship

Is androgen deprivation therapy protective against SARS-CoV-2 infection and related complications in prostate cancer patients?

2020 ◽  
Vol 72 (6) ◽  
Author(s):  
Alberto Dalla Volta ◽  
Francesca Valcamonico ◽  
Stefania Zamboni ◽  
Vittorio D. Ferrari ◽  
Salvatore Grisanti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation
Sign in / Sign up

Export Citation Format

Share Document